
Mahendra P Deonarain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3801602/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antibodies targeting cancer stem cells: A new paradigm in immunotherapy?. MAbs, 2009, 1, 12-25.	5.2	130
2	Targeted photodynamic therapy with multiplyâ€koaded recombinant antibody fragments. International Journal of Cancer, 2008, 122, 1155-1163.	5.1	75
3	Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?. Antibodies, 2018, 7, 16.	2.5	64
4	Emerging formats for next-generation antibody drug conjugates. Expert Opinion on Drug Discovery, 2015, 10, 463-481.	5.0	62
5	Modulation of Antibody Pharmacokinetics by Chemical Polysialylation. Bioconjugate Chemistry, 2008, 19, 643-650.	3.6	58
6	Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosesitizer conjugates suitable for photodynamic therapy. Photochemical and Photobiological Sciences, 2007, 6, 933-939.	2.9	46
7	Novel photosensitisers derived from pyropheophorbide-a: uptake by cells and photodynamic efficiency in vitro. Photochemical and Photobiological Sciences, 2010, 9, 1033-1041.	2.9	45
8	Modulating antibody pharmacokinetics using hydrophilic polymers. Expert Opinion on Drug Delivery, 2011, 8, 1221-1236.	5.0	38
9	Antibody-Directed Phototherapy (ADP). Antibodies, 2013, 2, 270-305.	2.5	35
10	Recombinant antibodies for cancer therapy. Expert Opinion on Biological Therapy, 2008, 8, 1123-1141.	3.1	27
11	Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile. PLoS ONE, 2015, 10, e0135039.	2.5	23
12	Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate. Oncotarget, 2017, 8, 25080-25096.	1.8	21
13	Miniaturised â€~antibody'-drug conjugates for solid tumours?. Drug Discovery Today: Technologies, 2018, 30, 47-53.	4.0	19
14	Phage display of chelating recombinant antibody libraries. Molecular Immunology, 2007, 44, 2860-2869.	2.2	16
15	Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy. Expert Opinion on Drug Discovery, 2021, 16, 613-624.	5.0	16
16	A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I. , 2000, 86, 561-569.		15
17	Tackling solid tumour therapy with small-format drug conjugates. Antibody Therapeutics, 2020, 3, 237-245.	1.9	14
18	Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression. Oncotarget, 2018, 9, 22945-22959.	1.8	11

#	Article	IF	CITATIONS
19	Ligand-targeted receptor-mediated vectors for gene delivery. Expert Opinion on Therapeutic Patents, 1998, 8, 53-69.	5.0	10
20	Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin. Protein Expression and Purification, 2013, 88, 157-163.	1.3	4
21	Abstract 2901: Gastric cancer antibody fragment drug-conjugates (FDCs): From concept to clinical development. , 2020, , .		2